Standard management of T2DM in obese individuals primarily involves lifestyle modifications, dietary changes, physical activity, and pharmacological interventions, including insulin, metformin, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose co-transporter-2 (SGLT2) inhibitors [3]. This evidence concerns the gene INS and type 2 diabetes mellitus.